Mr. Ken d'Entremont reports

MEDEXUS HOLDS ANNUAL MEETING OF SHAREHOLDERS AND ANNOUNCES ELECTION OF DIRECTORS

Medexus Pharmaceuticals Inc. held its virtual annual meeting of shareholders on Sept. 25, 2025. Medexus shareholders elected all nominees listed in Medexus's management information circular dated Aug. 12, 2025, as directors through the next annual meeting. Shareholders also voted in favour of the appointment of PricewaterhouseCoopers LLP as the company's auditor.

Detailed voting results for the election of directors are set out in the table below.

Shareholders also cast 14,240,037 (99.508 per cent) votes for and withheld 70,444 (0.492 per cent) votes from the appointment of PricewaterhouseCoopers LLP as the company's auditor. All proposals were therefore approved.

A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at SEDAR+.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology, and allergy, dermatology and rheumatology.

We seek Safe Harbor.